In a proactive move to address the growing public health crisis of pharmaceutical misuse, Japan’s health ministry has announced the addition of two key ingredients to its official “abuse potential” list. This update, finalized by a ministry subcommittee on Friday, brings the total number of monitored substances in common medicines from six to eight.

The new additions include **dextromethorphan**, a cough suppressant (antitussive) widely found in cold remedies, and **diphenhydramine**, an antihistamine frequently used for allergies and sleep aids. These substances have been identified as primary drivers in the surge of intentional overdoses reported across the country.

The Revised Pharmaceutical and Medical Device Law

This regulatory shift is not merely a guideline but a formal integration into Japanese law. Effective **May 2026**, the revised Pharmaceutical and Medical Device Law will codify these restrictions, transitioning them from administrative ordinances to statutory requirements.

According to analysis by Dr. Titus, this legal upgrade empowers authorities to enforce sales monitoring more strictly, ensuring that pharmacies and retailers are held accountable for dispensing high-risk products.

Stricter Protections for Minors

A central pillar of the new regulation focuses on protecting the most vulnerable demographic: individuals under the age of 18. The upcoming measures include:

• Purchase Limits: Minors will be restricted to buying only a single, small-volume package of products containing the designated ingredients.
• Supply Constraints: Each individual sale will be limited to a supply intended for only five to seven days of use.
• Identity Verification: Retailers will be required to exercise greater diligence in verifying the age and intent of young purchasers.

The official public announcement of these designations is expected in mid-February, allowing the pharmaceutical industry and retail sector a brief window to prepare for the May enforcement deadline.